Biocytogen Awarded U.S. Patent for RenLite® Common Light Chain Mouse Platform
June 21, 2024
Beijing, China, June 21, 2024 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) announced United States Patent and Trademark Office (USPTO) patent grant for independently developed RenLite® fully human common light chain mouse platform. RenLite® mice, developed using Biocytogen’s proprietary Size-Unlimited and Precise Chromosome Engineering (SUPCETM) technology, feature the in situ replacement of the […]
Join BiostartXcel Program and Accelerate Your Research
May 29, 2024
Are you ready to turbocharge your biotech research? At Biocytogen, we’re thrilled to support your journey with our cutting-edge gene editing services, humanized animal and cell models, and pharmacology services. Our BiostartXcel program is tailored specifically for biotech startups and small companies in the biotech sector, providing a robust suite of services designed to accelerate […]
